Assessing Mismatch Repair Expression by Immunohistochemistry in Colorectal Adenocarcinoma -Insight from a Tertiary Care Centre.

Q3 Medicine

The gulf journal of oncology Pub Date : 2024-05-01

Rachana Lakhe, Rajeev Doshi, Preeti Doshi, Amrutraj Patil, Ravindra Nimbargi

{"title":"Assessing Mismatch Repair Expression by Immunohistochemistry in Colorectal Adenocarcinoma -Insight from a Tertiary Care Centre.","authors":"Rachana Lakhe, Rajeev Doshi, Preeti Doshi, Amrutraj Patil, Ravindra Nimbargi","doi":"","DOIUrl":null,"url":null,"abstract":"Background: Microsatellite instability (MSI) is a pattern of hyper mutation that occurs at microsatellite level in the genome and result due to error in the mismatch repair system. MSI is caused by defective mismatch repair (MMR) genes associated with either hyper methylation of MMR genes or BRAF mutations. Anti-MLH-1, anti-MSH-2, anti-MSH-6 and anti-PMS2 monoclonal antibodies are used for Immunohistochemical analysis.Methods: The immunohistochemical expression of MSI proteins were assessed in 72 cases of colorectal carcinoma. These were classified based on the expression of MLH1, MSH2, MSH6 and PMS2 proteins.Results: There were 57 percent of cases showing loss of at least one antibodies, and 43 percent cases showing intact expression of all antibodies (MLH1, MSH2, MSH6 and PMS2).Conclusion: In conclusion, our study provides valuable insights into the expression of mismatch repair in colorectal adenocarcinoma through immunohistochemistry analysis conducted at our tertiary care centre. These findings hold significant clinical implications, suggesting further testing for BRAF and MLH1 Promoter Hypermethylation to confirm possibility of Lynch syndrome.Key words: IHC, MMR, CRC.","PeriodicalId":53633,"journal":{"name":"The gulf journal of oncology","volume":"1 45","pages":"35-41"},"PeriodicalIF":0.0000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The gulf journal of oncology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Microsatellite instability (MSI) is a pattern of hyper mutation that occurs at microsatellite level in the genome and result due to error in the mismatch repair system. MSI is caused by defective mismatch repair (MMR) genes associated with either hyper methylation of MMR genes or BRAF mutations. Anti-MLH-1, anti-MSH-2, anti-MSH-6 and anti-PMS2 monoclonal antibodies are used for Immunohistochemical analysis.

Methods: The immunohistochemical expression of MSI proteins were assessed in 72 cases of colorectal carcinoma. These were classified based on the expression of MLH1, MSH2, MSH6 and PMS2 proteins.

Results: There were 57 percent of cases showing loss of at least one antibodies, and 43 percent cases showing intact expression of all antibodies (MLH1, MSH2, MSH6 and PMS2).

Conclusion: In conclusion, our study provides valuable insights into the expression of mismatch repair in colorectal adenocarcinoma through immunohistochemistry analysis conducted at our tertiary care centre. These findings hold significant clinical implications, suggesting further testing for BRAF and MLH1 Promoter Hypermethylation to confirm possibility of Lynch syndrome.

Key words: IHC, MMR, CRC.

本刊更多论文

通过免疫组化评估结直肠腺癌中错配修复的表达--来自一家三级医疗中心的启示。

背景：微卫星不稳定性（MSI）是一种发生在基因组微卫星水平的高突变模式，是由于错配修复系统的错误造成的。MSI 由错配修复（MMR）基因缺陷引起，与 MMR 基因的过度甲基化或 BRAF 基因突变有关。抗MLH-1、抗MSH-2、抗MSH-6和抗PMS2单克隆抗体用于免疫组化分析：方法：对 72 例结直肠癌进行 MSI 蛋白的免疫组化表达评估。根据 MLH1、MSH2、MSH6 和 PMS2 蛋白的表达对这些病例进行分类：结果：57%的病例显示至少一种抗体缺失，43%的病例显示所有抗体（MLH1、MSH2、MSH6 和 PMS2）表达完整：总之，我们的研究通过在三级医疗中心进行的免疫组化分析，对错配修复在结直肠腺癌中的表达提供了有价值的见解。这些发现具有重要的临床意义，建议进一步检测 BRAF 和 MLH1 Promoter 过度甲基化，以确认林奇综合征的可能性：IHC、MMR、CRC。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

The gulf journal of oncology Medicine-Medicine (all)

CiteScore

0.90

自引率

0.00%

发文量